Dr. Ron P. Gallemore, M.D., Ph.D. - Founder and Director. Internationally recognized clinician, scientist and surgeon

/
KJP2459-Edit-sRGB-Full-Res-300ppi-450x300.jpg

Dr. Ron P. Gallemore, Founder and Director of the Retina Macula Institute, is an internationally recognized clinician and a world renowned scientist and surgeon.

Dr. Ron P. Gallemore received his undergraduate from the University of California, Irvine (UCI), where he graduated with Magna Cum Laude Honors. He earned his medical degree from the University of California, San Francisco (UCSF), where he graduated with highest honors and was awarded the “star” of class distinction by the Dean of the Medical School. As a member of the elite Medical Scientist Training Program (MSTP), he also completed his Ph.D. in Neuroscience, focusing on the physiology and biophysics of retinal function. He then trained at the Jules Stein Eye Institute, UCLA, where he completed his residency while concurrently establishing and directing an internationally recognized retinal research laboratory. For more advanced training, he completed the prestigious vitreoretinal surgery fellowship at Duke University under Dr. Robert Machemer, the founder of modern vitreoretinal surgery.

Dr. Gallemore has been awarded some of ophthalmology’s most prestigious awards, including the Heed and Knapp Fellowship Awards, the Dr. Charles Schepens Award and the Dr. Ronald G. Michels Fellowship Foundation Award, and was peer selected to receive the Jules Stein Eye Institute Alumni Research Award. In 2012, he was awarded the honorary Lifetime Achievement Award by the American Academy of Ophthalmology.

His research has been funded by the National Eye Institute, Research to Prevent Blindness, the Foundation Fighting Blindness, Fight for Sight, the University of California, and the National Science Foundation.

As a retina surgeon, Dr. Gallemore has performed over 15,000 surgical procedures and has helped develop new techniques. He has published more than 250 original articles, reviews, and book chapters, and has been an investigator in over 50 clinical trials.

Dr. Gallemore is also known for his athletic achievements including six 32-Mile Open Ocean Catalina Marathon Paddleboard Races, finishing in the top 20, the Molokai to Oahu 32 mile Open Ocean World Championship Paddle Board race in both the prone and stand-up divisions, considered the most challenging channels in the world, and numerous triathlons. He is fluent in Spanish and also enjoys surfing, golf and salsa dancing.

More information about Dr. Ron Gallemore is available on Wikipedia.

Education:

Undergraduate:
University of California, Irvine, Irvine, California,
B. S. School of Biology, Magna Cum Laude
September 1982 – June 1986

Medical School:
University of California, San Francisco, CA
M. D., School of Medicine, Ph.D., Neuroscience
September 1986 – May 1992

Internship:
Mercy Hospital and Medical Center, San Diego, CA
Transitional Internship
June 1992 – June 1993

Ophthalmology Residency:
Jules Stein Eye Institute, UCLA Medical Center, Los Angeles, CA
Ophthalmology Resident
July 1993 – June 1996

Fellowship:
Duke University Medical Center, Durham, NC
Vitreoretinal Surgery Fellowship
July 1996 – June 1998

Board Certification:
American Board of Ophthalmology

Licensure:
California – G78240
DEA – BG3932072

 

Professional Background:

Retina Vitreous Associates Medical Group
1127 Wilshire Blvd. Suite 1620
Los Angeles, CA 90017
July 1998-October 2007

Retina Macula Institute
Founder and Director
4201 Torrance Blvd., Suite 220
Torrance CA, 90503
Dec 2007-Present

 

Academic Positions:

Clinical Instructor, Jules Stein Eye Institute,
UCLA Clinical Instructor
1998-PresentClinical Instructor, Retina Division,
Duke University Eye Center
1995-1997

Conference Director
Duke Eye Center Fluorescein Angiography
1996-1997

Lecturer, Program in Biological Sciences
University of California, San Francisco
1990-1992

Teaching Assistant
Neuroanatomy, School of Medicine
University of California, San Francisco
1990

Teaching Assistant and Course Tutor
Physiology, Biochemistry, General Chemistry, Organic Chemistry,
Developmental and Cell Biology, Psychobiology, and Sensory
Physiology. Dept. of Biological Sciences
University of California, Irvine
1983-1986

Review Course Instructor and Organizer
“Catching Carbon Chemistry” and “Intro to General Chemistry”
University of California, Irvine

 

Awards and Honors:

2012 – Academy of Ophthalmology – Lifetime Achievement Award

2011 – Super Doctors Los Angeles – Southbay’s Top Doctors Award

2000 – Jules Stein Eye Institute Alumni Research Award

1999 – Jules Stein Eye Institute Alumini Research Award

1997 – Ronald G. Michels Fellowship Foundation Award

1997 – Heed/Knapp Fellowship, Heed Ophthalmic Foundation

1996 – Heed Fellowship, Heed Ophthalmic Foundation

1996 – Society of Heed Fellows Fellow, Heed Ophthalmic Foundation

1996 – Jules Stein Eye Institute Laboratory Research Award

1995 – Schepens International Society, Outstanding Research Paper Award, Mexico City

1995 – Jules Stein Eye Institute Laboratory Research Award

1995 – Jules Stein Eye Institute Resident Research Award

1994 – Dr. Henry and Lilian Nesburn Research Award Los Angeles Society of Ophthalmology

1993 – Robert J. Prentiss Original Research Award Mercy Hospital, San Diego, CA

1989, 1990 – National Eye Institute Research Service Award

1986 – Dean’s Summer Research Fellowship University of California, San Francisco

1985 – Fight for Sight Student Fellowship

1985 – Dr. W. F. Holcomb Research Scholar Award University of California, Irvine

1985 – Dean’s Academic Achievement and Service Award – University of California, Irvine

1984 – Phi Betta Kappa – Liberal Scholarship

1984 – Robert Ernst Prize for Excellence in Research in the Biological Sciences

1984 – Alpha Epsilon Delta Honor Society, University of California, Irvine

1984 – Swedish Club of Los Angeles Inc. Academic Scholarship Award

1983, 1984 – Chancellor’s Scholar, U.C. Irvine

1983 – Phi Beta Kappa Honor Society (Sophomore)

1983, 1984 – President’s Undergraduate Research Grant U.C. Irvine

1983, 1984 – Excellence in Research Award UC Irvine

1983 – Committee for Undergraduate Development Research Scholarship – U.C. Irvine

1982 – Excellence in Research Award Southern California Academy of Sciences

1982 – Scholarship for Academic Excellence and Community Service, RCU #324

 

Active Clinical Trials:

Principal Investigator
Alcon- C-10-083: A prospective, double-masked, active-controlled, single dose randomized study to assess the safety, tolerability, and efficacy of ESBA 1008 versus Lucentis in adult patients with exudative age-related macular degeneration (AMD)
(2012)

Principal Investigator
iDEAL- 2010-007-03-DME: A randomized, multi-center, phase 2 study evaluating the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with laser photocoagulation or Ranibizumab in adult patients with Diabetic Macular Edema.
(2012)

Principal Investigator
Allergan REACH-AGN-150998: A phase 2, randomized, double-masked comparison of the effects and safety of treatment with AGN-150998 and ranibizumab on retinal edema and BCVA in treatment-naïve patients with exudative age-related macular degeneration (AMD).
(2012)

Principal Investigator:
Allergan IST DME IIT-406: a randomized study to test the efficacy of Ozurdex versus Avastin on recalcitrant macular edema and macular function associated with diabetic retinopathy on patients with two or more prior intravitreal anti-VEGF drug injections.
(2012)

Principal Investigator
GSK- BAM114341: A phase 2, multi-center, randomized, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
(2012)

Principal Investigator
Novartis- CLFG316A2202: A multicenter, multiple dose study to assess the safety, tolerability, serum pharmacokinetics, and efficacy of intravitreal LFG316 in patients with neovascular age-related macular degeneration
(2012)

Principal Investigator
LUX Biosciences- LX-211-11: A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye
(2012)

Principal Investigator
Allergan BDP208397-001: A 12-Month, Multicenter, 2-Stage (Open Label, Dose Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
(2011)

Principal Investigator
Allergan- 1128277 – Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
(2011)

Principal Investigator
Regeneron- VGFT-OD-1009: A Double-Masked, Randomized, Active- Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema
(2011)

Principal Investigator
Novartis-CRFB002A2407: A 16-week evaluation of the novartis health management tool in assessing self-test visual function in patients with AMD treated with Lucentis
(2011)

Principal Investigator
Santen: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye
(2011)

Principal Investigator
Genentech-SHORE: A Multicenter, Randomized, Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion
(2011)

Principal Investigator
Genentech- MAHALO: A Phase IB/II, Multicenter, Randomized, Single-Masked, Sham-Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy
(2010)

Principal Investigator
Quan Nguyen READ3: Ranibizumab for Edema of the Macula in Diabetes; Protocol 3 with High Dose – the READ 3 study
(2010)

Principal Investigator
Regeneron: A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion
(2010)

Principal Investigator
Allergan: A 12-Month Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 ug Ozurdex as Adjunctive Therapy to Lucentis Compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration
(2010)

Principal Investigator
Valley Eye Retina PRESERVE: Pegaptanib for Retinal Edema Secondary to Dabetic Vascular Disease
(2009)

Principal Investigator
Nevanac Ist, Ron Gallemore: Exploratory, Randomized, Controlled Clinical Study Assessing the Efficacy of Nepafenac as Adjunctive Therapy for Patients with Clinically Significant Diabetic Macular Edema
(2009)

Principal Investigator
Alcon ALKOR: C-07-43 – A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients
(2009)

Principal Investigator
Genentech HORIZON: An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to RETINAL VEIN
OCCLUSION (RVO) who have completed a genentech-sponsored RANIBIZUMAB STUDY
(2009)

Principal Investigator
Genentech HARBOR: A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
(2009)

Principal Investigator
Alcon GATE: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Denegeration (AMD)
(2009)

Principal Investigator
Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
(2008)

Principal Investigator
Lucentis IST, Ron Gallemore: Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular degeneration
(2008)

Principal Investigator
QLT RADICAL BPDOCR 022: A Multicenter, Randomized, Single-Masked Study Comparing Reduced-fluence Visudyne – Lucentis Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD
(2007)

Principal Investigator
Novartis Denali: A 24 Month Randomized, Double Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteportin (Visudyne) Photodynamic Therapy Administered in Conjunction with Ranibizumab (Lucentis) Versus Ranibizumab (Lucentis) Monotherapy in Patients with Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration.
(2007)

Principal Investigator
Genentech FVF4165g BRAVO: A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Vein Occlusion
(2007)

Principal Investigator
Genentech FVF4166g CRUISE: A Phase III, Multi-Center, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion
(2007)

Sub-Investigator
Othera Pharmaceuticals OT-551-C04 OMEGA: A Randomized, Double-Masked, Dose Ranging, Multicenter, Phase II Study Comparing the Safety and Efficacy of OT-551 with Placebo to Treat Geographic Atrophy Associated with Age-Related Macular Degeneration.
(2007)

Sub-Investigator
AREDS 2 (Age-Related Eye Disease Study 2): A Multi-Center, Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-ChainPolyunsaturated Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Age-Related Macular Degeneration
(2007)

Sub-Investigator
CNTF2: A Phase II Study of Implants on Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants with Visual Acuity Impairment Associates with Atrophic Macular Degeneration
(2007)

Sub-Investigator
CNTF3: A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants with Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome
(2007)

Sub-Investigator
CNTF4: A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants with Retinitis Pigmentosa Using Visual Fields as the Primary Outcome
(2007)

Sub-Investigator
Genentech SAILOR FVF3689g: A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD).
(2006)

Sub-Investigator
VISTA: A Randomized, Single-masked, Multicenter, Phase 2 Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (VISUDYNE Therapy) in Combination with Intravitreal Injection of Either 0 mg, 1 mg, or 4mg of

Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne with Intravitreal Triamcinolone Acetonide (VisTA) Trial.

Sub-Investigator
Genentech FVF4168g RIDE: A Phase III, Double-Masked, Multi-Center, Randomized Sham Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus
(2007)

Sub-Investigator
TargeGen OPH-TG100801-002: An Open-Label Randomized, Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients with Choroidal Neovascularization Due to Age-Related Macular Degeneration
(2007)

Sub-Investigator
Allergan SIRIUS 211745-001-00: A 2-Year, Multi-Center, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections of AGN211745 in Patients with Subfoveal Choridal Neovascularization Secondary to Age-Related Macular Degeneration
(2007)

Principal-Investigator
GenVec: Protocol #GV-003.001: An Open-Label, Phase I, Single Administration, Dose Escalation Study of Ad PEDF.11D in Neovascular Age-Related Macular Degeneration (AMD) and Protocol #GV000.000 Long-Term Follow Up Protocol for GenVec, Inc. Gene Transfer Product Candidates in Clinical Development

Other Clinical Trials

• ISIS CS-7 “An open label study of the safety and efficacy of intravitreal ISIS 2922 in acquired immune deficiency syndrome patients with cytomegalovirus retinitis.”

• ISIS CS-9 “A randomized comparison of two dosage schedules of intravitreal ISIS 2922 for patients with advanced cytomegalovirus retinitis.”

• ProGancyclovir WV15376 “A randomized, controlled comparison of the safety and efficacy of RS-79070 an oral prodrug of gancyclovir, vs. IV gancyclovir as induction therapy for the treatment of newly diagnosed peripheral cytomegalovirus retinitis.”

• Roche ML 16356 “Open label safety study of Valganciclovir (RO 107-9070) in patients with CMV Retinitis and AIDS who have complications due to IV treatment.”

• Roche WV 15376 “A randomized, controlled comparison of the safety and efficacy of Valganciclovir vs. IV Ganciclovir as medication therapy for the treatment of newly diagnosed cytomegaloviruses.”

• Roche WV 15705 “An open label of the safety and tolerability of Valganciclovir, an oral prodrug of ganciclovir, for the treatment of cytomegalovirus retinitis in subjects with AIDS.”

• Pharmacia & Upjohn “A phase III randomized, multi-center, doublemasked, placebo controlled parallel group of in ethyl etiopurpurin (SnET2) photodynamic therapy in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.”

• Alcon Research, LTD “An evaluation of efficacy and safety of a subtenon’s injection of anecortave acetate sterile suspension (60 mg/mL) versus placedo in patients with exudative AMD following treatment with photodynamic therapy using Visudyne.”

• QLT Pharmaceuticals BPD OCR 009 “A randomized, placebo-controlled, double-masked, multicenter, phase III study of the effect of Visudyne therapy in occult with no classic subfoveal CNV secondary to AMD.”

• QLT Pharmaceuticals BPD OCR 011 “A randomized, placebo controlled, double-masked, multicenter, phase II/III study of the effect of visudyne therapy in minimally classic subfoveal CNV secondary to AMD.”

• Oculex Pharmaceuticals, INC. “A phase I/II randomized, double-masked, multicenter, dose-ranging, placebo controlled trial to assess the safety, tolerability and efficacy of DEX PS DDS in the treatment of inflammation following pars plana vitrectomy.”

• Advanced Corneal Systems, INC Protocol VIT-02-08961X “Phase III safety and efficacy study of vitrase for ophthalmic intravitreal injection for clearance of severe vitreous hemorrhage.”

• Novartis Pharmaceuticals Corporation “A randomized, controlled study on the efficacy and safety of Sandostatin LAR in the therapy of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR).”

• Apheresis Technologies, Inc. “A multicenter, prospective, randomized, double-masked study comparing the safety and efficacy of membrane differential filtration to a placebo treatment in patients with nonexudative age-related macular degeneration.”

• Eli Lily and Company Protein Kinase CB inhibitor—Diabetic Macular Edema Study (PKC-DMES)

• Iris Medical Occult subfoveal choroidal neovascular membranes “Transpupillary Thermotherapy of occult subfoveal choroidal neovascular membranes in Patients with Age-Related Macular Degeneration (The TTT4CNV Clinical Trial).”

• Agouron Pharmaceuticals INC. “A phase II, randomized, double-masked, placebo controlled study of the matrix matalloprotease inhibitor AB3340 in patients with subfoveal choroidal neovascualrization associated with age related macular degeneration.”

• ISTA Pharmaceuticals “Phase III safety and efficacy study of Vitrase™ (Hyaluronidase) for ophthalmic intravitreal injection for clearance of severe vitreous hemorrhage.”

• Retina Vascular Surgery Branch Retinal Vein Occlusion Study “The photocoagulation BRVO ST is designed to approach the anatomical lesion, arteriolar compression of a venule at the crossing site, by incising the vascular sheath-“sheathotomy.” This study has used the guidelines of the original BRVO and enrolling patients whose eyes are ineligible for that study. Preliminary data suggest a rapid opening of the obstructed venule and re-establishment of the capillary bed blood flow with concomitant
improvement in vision. Eligible patients are those with macular hemorrhage, chronic occlusions more than 180 days and eyes
unresponsive to prior standard focal laser.”

• EyeTech Pharmaceuticals, Eye001 “A phase II/III randomized, single masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of Eye001 (anti-vegf pegylated aptamer) given at 6 weekly intervals for 54 weeks in patients with exudative age-related macular degeneration.”

Research Grants

DurationPositionAmountSource and Title

1 Year - 1997/1998, PI, $2,500, Duke Eye Center Research Grant,
“Application of differential display to identify genes expressed during retinal pigment epithelial cell proliferation”.

1 Year - 1997/1998, Co-PI, $2,500, Duke Eye Center Research Grant,
“Pharmacokinetics offluocinolone/5-fluoruracil release in the presence of intraocular gas tamponade”

1 Year - 1995/1996, PI, $15,000, Jules Stein Eye Institute Research,
Grant (Patricia Morrison Fund), “Ion channels and fluid transport in human retinal pigment epithelium”.

1 Year - 1995/1996, PI, $2,500, Research Grant -- Alumni Association of the Jules Stein Eye Institute,
“Video library of surgical ophthalmology”

1 Year - 1994/1995, PI, $15,000, Jules Stein Eye Institute Research,
Grant (Stellla-Joseph Fund) “Ion transport pathways in human retinal pigment epithelium”.

1 Year - 1994/1995, PI, $20,000, Stein-Oppenheimer Research Grant, University of California, Los Angeles,
“Ion transport mechanisms inhuman retinal pigment epithelium”.

2 Years - 1992/1994, Co-PI, $20,000, National Eye Institute R01 Research Grant,
“Ion transportation cultured human retinal pigment epithelium”

1 Year - 1985/1986, PI, $5,000, Retinitis Pigmentosa Foundation, Research Grant,
“Ionic mechanisms of photoreceptor-retinal pigment epithelium responses”

1 Year - 1985/1986, PI, $2,500, Retinitis Pigmentosa Foundation Research Grant,
“Anion transport mechanisms at the basolateral membrane of the retinal pigment epithelium”

Summer 1985, PI, $1,200, Fight for Sight Student Fellowship,
“Mechanisms of pH regulation in the avian retina”

1 Year - 1994/1995, PI, $1,000, President’s Undergraduate Research Grant, U.C. Irvine,
“Neutron activation analysis for determination of Uranium and Thorium”

1 Year - 1993/1994, PI, $1,000, President’s Undergraduate Research Grant, U.C. Irvine,
“Brain transplantation in the polyclad flatworm, Notoplana acticola”

1 Year - 1981/1982, PI, $5,000, Research Grant, Southern California Academy of Sciences,
“Retinotectal and intertectal relay mechanisms in the frog visual system”

Peer Reviewed Publications

1. Gallemore, RP and Fraser, SE (1982) New insights into the function of the intertectal relay system of xenopus laevis. J. So. Ca. Acad. Sci.: 1-20

2. Gallemore, RP and Fraser, SE (1983) A possible function of the intertectal relay system in a primitive depth perception for xenopus laevis. UCI J. Undergrad. Res. Bio. 13: 344-58.

3. Gallemore, RP and Koopowitz, H (1984) Nerve repair and behavioral recovery following transplantation of the brain to the tail in notoplana acticola, a polyclad flatworm. UCI J. Undergrad. Res. Bio. 14: 1-17

4. Gallemore, RP, Griff, ER and Steinberg, RH (1988) Evidence in support of a photoreceptoral origin for the “light-peak substance.”
Invest. Ophthalmol Vis. Sci. 29: 566-571.

5. Nao-I N, Neilson, SE, Gallemore, RP. and Steinberg, RH (1989) Effects of melatonin on the check retinal pigment epithelium:
membrane potentials and light-evoked responses. Exp. Eye Res. 49: 1-17.

6. Gallemore, RP, and Steinberg, RH (1989) Effects of DIDS on the chick retinal pigment epithelium: II mechanism of the light peak and other responses originating at the basal membrane. J Neurosci 9: 1977-1984.

7. Gallemore, RP. and Steinberg, RH (1989) Effects of DIDS on the check retinal pigment epithelium: I. Membrane potentials, apparent resistances and mechanisms. J Neurosci. 9: 1968-1976.

8. Nao-I, Gallemore, RP, and Steinberg, RH (1990) Effects of cAMP and IBMX on the check retinal pigment epithelium: membrane potentials and light-evoked responses. Invest. Ophthalmol. Vis. Sci. 31:54-66.

9. Gallemore, RP and Steinberg, RH (1990) Effects of dopamine on the chick retinal pigment epithelium: Membrane potentials and lightevoked responses. Invest. Ophthalmol. Vis. Sci. 31: 67-80

10. Gallemore, RP and Steinberg, RH (1991) Cobalt increases photoreceptor-dependent responses of the check retinal pigment
epithelium. Invest. Ophthalmol. Vis. Sci. 32:3041-3052.

11. Fujii, S, Gallemore, RP. Hughes, B and Steinberg, RH (1991) Direct evidence for a basolateral membrane Cl conductance in toad retinal pigment epithelium. Am. J. Physiol. 262:C374-C383.

12. Gallemore, RP (1992) Ionic mechanism of the light-peak voltage of the DC Electroretinogram. (Ph.D. Thesis) Univ. of California, San Francisco, San Francisco, CA

13. Gallemore, RP, Hernandez, E, Tayyanipour, R, Fujii, S and Steinberg, RH (1993) Basolateral membrane Cl- and K+ conductances
in the dark-adapted chick retinal pigment epithelium. J Neurophysiol. 70: 1656-1668

14. Gallemore, RP and Steinberg, RH (1993) Light-evoked modulation of basal membrane CL- conductance in chick retinal pigment
epithelium: the light peak and fast oscillation. J. Neurophysiol. 70: 1669-1680.

15. Hu, J, Gallemore, RP, Bok, D, Lee, AY, and Frambach, D (1994) Localization of Na/ KATPase on cultured human retinal pigment
epithelium. Invest. Ophthalmol. Vis.Sci. 35(10): 3582-88.

16. Li, JD, Gallemore, RP, Dmitriev, AV, and Steinberg, RH (1994) Light-Dependent hydration of the space surrounding photoreceptors in check retina. Invest. Ophthalmol. Vis. Sci. 35:2700-11.

17. Gallemore, RP, Li, J-D. Govardovskii, VJ and Steinberg, RH (1994) Calcium gradients and light-evoked calcium changes outside rods in the intact cat retina. Visual Neurosci 11:753-61.

18. Gallemore, RP. and Bokosky, J (1995) Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: Modified technique allowing use of larger corneal grafts. Cornea 14(1):33-38.

19. Hernadez, H, Hu J, Frambach, D and Gallemore, RP. (1995) Potassium Conductances in cultured bovine and human retinal
pigment epithelium. Invest. Ophthalmol. Vis. Sci. 36:113-122.

20. Ju, J., Gallemore, RP, Bok, D and Frambach, D (1995) Chloride transport in Cultured fetal human retinal pigment epithelium.
Exp. Eye Research 62:443-48

21. Gallemore, RP, Bokosky JE (1995) Penetrating keratoplasty with vitreoretinal surgery using the Eckardt temporary
keratoprosthesis; modified technique allowing use of larger corneal grafts. Cornea. Jan; 14(1):33-8

22. Hernandez EV, Hu JG, Frambach DA, Gallemore RP (1995) Potassium conductances in cultured bovine and human retinal
pigment epithelium. Invest. Ophthalmol Vis Sci. Jan; 36(1):113-22.

23. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. (1998) Intravitreal sustained-release cyclosporine in the treatment of experimental Uveitis. Ophthalmology. Jan;105(1):46-56.

24. Gallemore RP, Green J, Shorr N, Goldberg RA. (1999) Use of isobutyl cyanoacrylate tissue adhesive to stabilize mucous membrane grafts in total socket reconstruction. Ophthal Plast Reconstr Surg. May;15(3): 210-2.

25. Jumper JM, Machemer R, Gallemore RP, Jaffe GJ. (2000) Exudative retinal detachment and retinitis associated with acquired
syphilitic uveitis. Retina. 20(2):190-4.

26. Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. (2000) Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina. 20(2):115-20.

27. Jumper JM, Gallemore RP, McCuen BW 2nd, Toth CA. (2000) Features of macular hole closure in the early postoperative period using optical coherence tomography. Retina. 20(3):232-7.

28. Perkins SL, Gallemore RP, Yang CH, Guo H, Ashton P, Jaffe GJ. (2000) Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. Retina. 20(5):514-9.

29. Gallemore RP, Jumper M (2000) Ins and Outs of Silicone Oil Review of Ophthalmology 9/01/00

30. Gallemore RP, Boyer DS (2001) Retinal Detachment: The Best Treatment is Prevention Review of Ophthalmology. (4);121-1204/10/01

31. Gallemore RP, Boyer DS. (2002) Save your sight. Eye disease and HIV. Posit Living. 2001 Dec-2002 Jan;10(7):29-30.

32. Gallemore RP, Boyer DS (2002) Buckle, vit or bubble: RD management options. Review of Ophthalmology 9(04):4/15/02

33. Gallemore RP, Thomas EL, Boyer DS (2002) Minimally Invasive Vitreoretinal Surgery Review of Ophthalmology. 9(11): 11/19/02

34. Navas F, Boyer DS, Thomas EL, Novak RL, Chu TG, Gallemore RP. Management of pupillary block glaucoma in phakic patients after vitrectomy with silicone oil injection. Am J Ophthalmol. 2002 Oct;134(4):634-5.

35. Boyer DS, Gallemore RP Clinical trials assess rheopheresis Review of Ophthalmology 10(08):8/15/03

36. Gallemore RP, Boyer DS (2003) AMD treatment update. Ophthalmology Management, March 2003

37. Rajasekaran SA, Hu J, Gopal J, Gallemore R, Ryazantsev S, Bok D, Rajasekaran AK. Na,K-ATPase inhibition alters tight junction
structure and permeability in human retinal pigment epithelial cells. Am J Physiol Cell Physiol. 2003 Jun;284(6):C1497-507.

38. Taban M, Thomas EL, Boyer DS, Novack RL, Chu TG, Gallemore RP. Efficacy of verteporfin photodynamic therapy on laser-induced choroidal neovascularization and the ancillary effect on diabetic microvasculopathy. Curr Eye Res. 2004 Apr;28(4):291-5.

39. Marmorstein AD, Rosenthal R, Stanton JB, Yocom J, Bakall B, Schiavone MT, Wadelius C, Gallemore RP, Marmorstein LY, Peachey NS, and Strauss O. (submitted).

40. Gallemore RP, Boyer DS (2004) Intravitreal Kenalog Injections. EyeNet, in press.

Book Chapters and Reviews

1. Miller, SS, Hughes, BA, and Gallemore, RP. Fluid transport in the retinal Pigment epithelium. Duane’s Textbook of Clinical Ophthalmology. (in prep)

2. Hughes, BA, Gallemore, RP and Miller, SS. Ion transport mechanisms in the retinal pigment epithelium. In: J Dowling, ed Physiological Reviews. (in prep)

3. Gallemore, RP, and Goldberg, RA (1996) Videotape library of surgical ophthalmology. Jules Stein Eye Institute, UCLA Medical Center.

4. Gallemore RP, Hughes BA and Miller SS (1997) Retinal pigment epithelial Transport and its relationship to the electroretinogram. In: N. Osborne and G. Chader, eds. Progress in Retinal and Eye Research.

5. Hughes, BA, Gallemore, RP and Miller, SS (1998) Transport mechanisms in the retinal pigment epithelium. In: The retinal pigment epithelium: function and disease. Marmor MF, Wolfensberger TJ, editors. New York: Oxford University Press; p. 103-34.

6. Gallemore, RP, Maruiwa, F and Marmor MF (1998) Clincial electrophysiology of the retinal pigment epithelium. In: M.F. Marmor and T. J. Wolfensberger, eds. The Retinal Pigment Epithelium: Function and Disease.

7. Gallemore RP, Hughes BA and Miller SS (1998) Light-induced responses of the Retinal pigment epithelium. In: M.F. Marmor and T. J. Wolfensberger, eds. The Retinal Pigment Epithelium: Function and Disease.

8. Gallemore RP, McCuen B II. (2000) Silicone oil tamponade in Vitreoretinal surgery. In: S. Ryan ed., Retina, Chapter 127.

9. Gallemore RP. (2000) Treatment update: Dry Macular Degeneration. Macular Degeneration Partnership Web Site Review, 06/01/00 (www.amd.org)

10. Gallemore RP. (2000) Treatment update: Wet Macular Degeneration. Macular Degeneration Partnership Web Site Review, 07/01/00 (www.amd.org)

11. Gallemore RP. (2000) Ask the doctor: macular degeneration. Macular Degeneration Partnership Web Site Review, 06/01/00
(www.amd.org)

12. Gallemore RP, Boyer DS (2003) Nutrition and the retina. Macular Degeneration Partnership Web Site Review, 03/01/03 (www.amd.org)

13. Gallemore RP, Kaiser P, Han D. (2003) Article review: Hypertensive retinopathy more common in blacks. Review of Ophthalmology, 10(05):5/15/03

14. Gallemore RP, Kaiser P, Han D. Insulin Lispro Benefits Pregnant Women with Diabetic Retinopathy. Review of Ophthalmology,
10(05):5/15/03

15. Gallemore RP (2003) Product review: Macular degeneration supplement. Ophthalmology Management, June 2003

16. Gallemore RP (2004) Product review: Supplement for optic nerve health. Ophthalmology Management, January 2004.

17. Gallemore RP, McCuen B II. (2005) Silicone oil tamponade in vitreoretinal surgery. In: Ryan S, ed., Retina. (in prep.)

Presentation/Abstracts

1. Gallemore, RP, Calvin Chou, and Madeline Eells (2010) Monthly Versus Prn Ranibizumab for Neovascular Age-related Macular Degeneration: a Randomized Phase 2 Open-label Study Using High Resolution OCT (ASRS)

2. Gallemore, RP, Calvin Chou, and David Nguyen (2010) Nucleoside Analogue Reverse Transcriptase Inhibitor- induced Retinal Degeneration in HIV-positive patient resembles Gyrate Atrophy (ASRS) Ron P. Gallemore 22

3. Steinberg, RH, Gallemore, RP, and Griff, E (1987) Origin of the light peak: Contribution from the neutral retina. Invest. Ophthalmol. Vis Sci (ARVO)28: 402.

4. Gallemore, RP. and Steinberg, RH (1987) Effects of the putative anion Transport inhibitor DIDS on the RPE basal membrane and the c-wave. Invest. Ophthalmol. Vis. Sci. (ARVO) 28: 382.

5. Gallemore, RP, and Steinberg RH (1987) Effects of cobalt and low calcium on light-evoked (K+)o changes in the sub retinal space and on the chick dc electroretinogram. Soc. Neurosci. Abstr. 13: 1049.

6. Steinberg, RH and Gallemore, RP. (1988) Effects of dopamine on RPE membrane Potentials and light-evoked responses in check. Invest. Ophthalmol. Vis. Sci.(ARVO) 29: 100.

7. Nao-I, N, Gallemore, RP. and Steinberg, RH (1988) Effects of camp on RPEMembrane potentials and Light-evoked responses in check. Invest. Ophthalmol. Vis. Sci. (ARVO) 29:100

8. Gallemore, RP, and Steinberg, RH (1988) Light-evoked changes in (Ca2+). In chick Retina. Invest. Ophthalmol. Vis. Sci. ARVO) 29: 103.

9. Gallemore, RP, and Steinberg, RH (1988) Evidence for a Cl-conductance in Chick-retinal pigment epithelium that may contribute to responses originating at the basal membrane. Soc. Neurosci. Abstr 14:357.

10. Gallemore, RP, Yamamoto, F, Steinberg, RH (1990) (Ca2+). Gradients and light-evoked (Ca2+). Changes in cat retina, in vivo. Soc. Neurosci. Abstr. 16:714.

11. Fujii, S, Gallemore, RP. Hughes, B. and Steinberg, R.H. (1990) Evidence for a basolateral membrane Cl- conductance in toad retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO) 31: 388.

12. Ng, C., Gallemore, RP. and Steinberg, R.H. (1991) The Cl- transport inhibitor, furosemide, selectively blocks light-evoked responses of the chick retinal pigment epithelium basal membrane. Clinical Res. 39: 128A.

13. Li, J.D., Gallemore, RP. And Steinberg, R. H. (1991) Effects of systemic hypoxia on (Ca2+)o in the intact cat retina. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 32:837.

14. Hernandez, E., Gallemore, RP. Tayyanipour, R., Fujii, S., and Steinberg, R.H., (1991) Basal membrane Cl- and K+ conductances in chick retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 32:837.

15. Gallemore, RP. and Steinberg, R.H. (1991) The light peak of the DC ERG is associated with an increase in Cl- conductance in chick RPE. Invest. Ophthalmol. Vis. Sci. (ARVO aster) 32: 837.

16. Li, J.D., Gallemore, RP, and Steinberg, R.H. (1992) Light induced increase in Subretinal space volume in chick retina. Invest. Ophthalmol. Vis. Sci. (ARVO aster) 33:913.

17. Hu, J., Lee, A.Y., Bok, D., Gallemore, RP. and Frambach, D. (1993) Electrophysiological localization of Na/K ATPase on confluent monolayers of cultured human RPE. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 34:1445.

18. Hernandez, E., Frambach, D. A., Bok, D., Farber, D. and Gallemore, RP. (1993) Apical and basolateral membrane potassium conductances in cultured monolayers of fetal bovine and human RPE. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 34: 873.

19. Bokosky, J., Gallemore, RP. Mani, H., Poliner, L., Smith, M., Bitner, D., Lipton, B. and Robinson, F. (1993) Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: A modified technique allowing use of larger corneal grafts. Cornea (Supplement, Eye Bank Assoc. Meeting, San Diego, CA, June 1993).

20. Gallemore, RP. and Bokosky, J. (1993) Penetrating keratoplasty with Vitreoretinal surgery utilizing the Eckardt temporary keratoprosthesis: Modified technique allowing use of larger corneal grafts. (Supplement, Eye Bank Assoc. Meeting, Chicago, Nov. 1993).

21. Gallemore, RP. Judge, A. and Hoft, R. (1994) A case of fungal keratitis caused by Chaetomium. Ocular Micro. Immune. Group, San Francisco, CA

22. Gallemore, RP. Hernandez, E.V., and Steinberg, R.H. (1994) Choroidfree preparation of explant retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci (ARVO Abstr.) 35: 1761.

23. Hu, J. G., Bok, D., Frambach, D.A. and Gallemore, RP. (1995) Betaadrenergic receptors activate basal membrane ion channels in cultured fetal human RPE. Invest. Ophthalmol. Vis. Sci. (ARVO Abstr) 36: S587.

24. Gallemore, RP. Hu, H.G., Frambach, D.A. and Bok, D. (1995) Ion transport pathways in cultured human retinal pigment epithelium. Fifth Biennial Schepens International Society Meeting. Mexico City, Mexico.

25. Gallemore, RP. Hu, J.G., Frambach, D.A. and Bok, D (1995) Ion transport in cultured human retinal pigment epithelium. Invest.
Ophthalmol. Vis. Sci (ARVO Abstr) 36: S216.

26. Hu, J., Gallemore, RP. Maruiwa, F. and Bok, B. (1996) Retinal potassium modulates multiple ion transport mechanisms in cultured human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci (ARVO Abstr.) 37: S229.

27. Maruiwa, F., Gallemore, RP, Takahira, M., Hughes, B., Hu, J. and Bok, B (1996) Membrane polarization of potassium conductances in cultured human retinal pigment epithelium Invest. Ophthalmol. Vis. Sci (ARVO Abstr) 36: S229.

28. Maruiwa, F., Gallemore, RP. Hu, J. and Bok, B. (1997) Nonsteroidal anti-inflammatory drugs (NSAIDS) modulate chloride channels in human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 38: S467.

29. Chen, J., Duker, J., Kim, V., Gallemore, RP. Jaffe, G. J., and Ashton, P. (1997) A 1.5 year gancyclovir implant for CMV retinitis. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38: S1103.

30. Wang, X. C., Yang, D. C. S., Cousin, S.W., Gallemore, RP. Ashton, P. and Jaffe, G.J. (1997) Intravitreal sustained release cyclosporine A (CsA) in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. (ARVO abstr) 38: S211.

31. Yang, C.C., Gallemore, RP, Niccolo, M., Kasahara, N., Ashton, P. and Jaffe, G. J. (1997) Retinoic acid (RA) intravitreal implants for the treatment of experimental proliferative vitreoretinopathy (PVR)-pharmacokinetics and ocular toxicity. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38:211.

32. Gallemore, RP, Yang, C.C., Guo, H., Cynkowshi, T., Synkowska, G., Ashton, P. and Jaffe, G. J. (1997) Inhibition of proliferative
vitreoretinopathy (PVR) using a fluocinolone/5-fluorouracil sustained release pellet. Invest. Ophthalmol. Vis. Sci (ARVO abstr) 38: S211.

33. Toth CA, Gallemore RP, Jumper JM. (1997) APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY (OCT) IN SURGICAL MANAGEMENT OF MACULAR DISEASE. Vitreous Society Meeting.

34. Gallemore RP, Thomas EL (2000) High Definition Video of High Speed Indentation Delamination. American Acad, Ophthal., Dallas.

33. Boyer, Ds, Gallemore, RP, (March 2007) “Changing Approaches to Diabetic Retinopathy”, Review of Ophthalmology/pages 88 – 92.

Newsletter Articles and Brief Review

Gallemore, RP (May/June 2000) “Treatment Update: Dry Macular Degeneration” The Observer

Gallemore, RP (Winter 2000) “Dry Macular Degeneration” The Observer

Gallemore, RP (October V2, Issue 1) “Gallemore’s Corner: Not Diabetes Again! Treatment Update II Clinical Studies” The Open Angle

Gallemore, RP (Spring 2000) “Millennium Treatments: Wet Macular Degeneration” Scene

Gallemore, RP (Summer 2000) “Millennium Treatments: Dry Macular Degeneration” Scene

Gallemore, RP (Summer 2000) “Management Strategies for Retinal Detachment After Cataract Surgery” Ocular Surgery News

Gallemore, RP (Spring 2001) “The Peripheral Retina: What to Look for and When to Refer” The Observer, The Open Angle

Gallemore, RP (Summer 2001) “Pre-Operative Evaluation of the LASIK Patient: The Retina Perspective” The Observer, The Open Angle

Gallemore, RP (Fall 2001) “Retinal Vein Occlusions: Make the Diagnosis” The Observer, The Open Angle

Gallemore, RP (Winter 2001) “Retinal Vein Occlusions: Treatment Update” The Observer, The Open Angle

Gallemore RP, Boyer DS (Summer 2002) White Dots and Blind Spots: Part 1 (Observer, The Open Angle)

Gallemore RP, Boyer DS (Fall 2002) White Dots and Blind Spots: Part 2 (Observer, The Open Angle)

Gallemore RP, Boyer DS (Winter 2002) Nutrition and the Retina: What should we tell out patients? (Observer, The Open Angle)

Gallemore RP, Boyer DS (Spring 2003) Wolfberry and more: What other antioxidants may help our patients? (Observer, The Open Angle)

Gallemore RP, Boyer DS (Summer 2003) AMD treatments in the pipeline (Observer, The Open Angle)

Gallemore RP, Boyer DS (Fall 2003) Intravitreal Kenalog injections: A “cure-all” for macular disease? (Observer, The Open Angle)

Gallemore RP, Boyer DS (Winter 2003) Toxic Maculopathies: A Responsibility to Screen (Observer, The Open Angle)

Gallemore RP, Boyer DS (Spring 2004) Optic Neuropathies with Disc Edema: Differential Diagnosis and Management (Observer, The Open Angle)

Gallemore RP (August 2004) Wet macular degeneration: clinical research update.” The Open Angle, The Observer

Gallemore RP, Boyer DS (Summer 2004) Clinical Research Update: Wet Macular Degeneration, Observer, The Open Angle, and The Rio Hondo Optometric Society Clinical Update

Manuscripts in Preparation

• Gallemore, RP, Hu, J, Hughes, B, Takahira, M and Bok, B. Beta 2 adrenergic receptors activate cyclic AMP-dependent chloride channels in cultured human retinal pigment epithelium in prep for Am. J. Physiol.• Gallemore, RP, Judge, A., and Hoft, R. A case of fungal keratitis caused by Chaetomium in prep. Cornea

• Maruiwa, F, Gallemore, RP, Hu, J, Hughes, B, Takahira, M and Bok, B. Membrane polarization of potassium channel subtypes in human retinal pigment epithelium. in prep for Invest. Ophthalmol. Vis. Sci.

• Gallemore, RP, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Nonsteroidal anti-inflammatory drugs modulate Cl channels in human retinal pigment epithelium in prep. for Invest. Ophthal. Vis. Sci.

• Gallemore, RP, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Purinergic type 2 receptors modulate Cl and K channels in human retinal pigment epithelium. in prep. for Invest. Ophthalmol. Vis. Sci.

• Maruiwa, F, Gallemore, RP, Hu, J. and Bok, B. Electrogenic HaHCO3 cotransport in human retinal pigment epithelium. in prep. for Invest. Ophthalmol. Vis. Sci.

• Maruiwa, F, Gallemore, RP, Hu, J. and Bok, B. Electrophysiological effects of transepithelial osmotic gradients in human retinal pigment epithelium in prep. for Exp Eye Res.

• Gallemore, RP, Maruiwa, F, Hughes, B, Takahira, M, Hu, J and Bok, B. Swelling activated chloride channels in human retinal pigment epithelium in prep for Am. J. Physiol.

• DCS, Yang, Wang W-C, Cousin SW, Gallemore, RP, Ashton, P, and Jaffe, GJ. Intravitreal sustained release cyclosporine A (CsA) in the treatment of experimental uveitis in prep for Invest. Ophthalmol. Vis. Sci.

• Gallemore, RP, Maruiwa, F, Heckenlively, J, Lewis, R, Sidikaro, Y. Lacunar loss of choriocapillaris in select retinal dystrophies in prep for Survery of Ophthalmol

• Gallemore, RP, Yang, CC, Guo, H, Cynkowshi, T, Synkowska, G, Ashton, P. and Jaffe, G. J. Inhibition of proliferative vitreoretinopathy (PVR) using sustained-release intravitreal fluocinolone/5-fluoruracil co-drug in prep for Invest. Ophthalmol Vis. Sci.

• Gallemore, RP, Jumper, JM, and Toth, C, Application of ocular coherence tomography in the diagnosis and management of macular disease (in prep)

• Gallemore, RP, and Toth, C. Role for Vitreoretinal structure in the pathogenesis of senile retinochisis in prep for Am. J. Ophthalmol.

Research Projects

• Gallemore, RP, Roberts, W, and Jaffe, G. Application of differential display to identify genes expressed during retinal pigment epithelial cell proliferation. (Advisor: Dr. Glenn Jaffe)

• Gallemore, RP, Jumper, J.M., and McCuen, B.W. II Axial length measurements with silicone oil tamponade. (Advisor: Dr. Brooks McCuen II)

• Perkins, S, Gallemore, RP, Yang, C.C. and Jaffe, G. Pharmacokinetics of fluocinolone/5-fluoruracil release in the presence of intraocular gas tamponade. (Advisor: Dr. Glenn Jaffe.)

• Yang, CC, Gallemore, RP, Niccolo, M, Kasahara, N, Ashton, P and Jaffe, GJ. Retinoic acid (RA) intravitreal implants for the treatment of experimental proliferative vitreoretinopathy (PVR) (Advisor: Dr. Glenn Jaffe)

• Chen, J, Duker, J, Kim, V, Gallemore, RP, Jaffe, GJ and Ashton, P. A 1.5 year gancyclovir implant for CMV retinitis. (Advisor: Dr. Glenn Jaffe)

• Gallemore, RP, and Toth, C. Application of ocular coherence tomography for the diagnosis and management of macular disease. (Advisor: Dr. Cynthia Toth)

• Steuer, E. and Gallemore, RP. Novel methodologies for mammalian retinal pigment epithelium culture and transplantation. (Advisor: Dr. Glenn J. Jaffe)

American Academy of Ophthalmology Course Instructor

2001-2003 Mccuen B, Jumper LM, Gallemore RP. Silicone Oil in Vitreoretinal Surgery. American Acad, Opthal.

2003-2006 Proliferative Vitreoretinopathy

2000 Gallemore, RP, Thomas EL. High Definition Video of High Speed Indentation Delamination. American Acad, Opthal., Dallas

Selected Lectures

1982 – 1983 “What the frogs eye tells the frogs brain.” Student Speaker’s Forum Community Lecture Series, University of California, Irvine.

1984 – 1985 “From heads to tails: Brain transplantation in the polyclad flatworm” Student Speaker’s Forum Community Lecture Series, University of California, Irvine.

1985 – 1986 “How the eye sees: Insights from the electroretinogram.” Student Speakers Forum Community Lecture Series, University of California, Irvine.

07/88 “Glucose control and amyloid proteins.” Program in Biological Sciences Lecture Series, University of California, San Francisco.

05/89 “Neuronal mechanisms of rheumatoid arthritis.” Program in Biological Sciences Lecture Series, University of California, San Francisco.

05/93 “Bechet’s disease associated with aseptic meningitis.” Rounds Lecture, Mercy Hospital and Medical Center, San Diego, CA

07/93 “Hyphema Management” Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA

07/93 “Ocular trauma: The ruptured globe.” Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA

08/93 “Oculoplastics and trauma” Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA

09/93 “Pterygium Surgery” Rounds Lecture, UCLA-Harbor Hospital, Torrance, CA

12/93 “Pahtologic myopia” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

02/94 “Age -related extra macular disciform degeneration” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

03/94 “Fungal keratitis.” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

05/94 “Ion Transport in Cultured Human RPE” Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA

10/94 “Painless proptosis.” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

10/94 “Penetrating keratoplasty with Vitreoretinal surgery utilizing temporary keratoprostehses: modified techniques allowing use of larger corneal grafts.” Ocular Microbiology and Immunology Group, Chicago, IL.

04/95 “Posterior polymorphous dystrophy.” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

05/95 “Laser retinopexy of peripheral retinal lesions.” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA.

05/95 “Fluid transport and ion channels in human retinal pigment epithelium.” Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA

08/95 “Physiology and pathophysiology of the foveal avascular zone.” Basic Science Lecture Series, Grand Rounds, Jules Stein Eye Institute, Los Angeles, CA

09/95 “The DC Electroretinogram: Its Discovery and Significance.” Roy H. Steinberg, M.D., PhD., Festschrift Celebration, U.C. San Francisco, CA

01/96 “Acute vision loss associated with intranasal cocaine abuse” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

03/96 “Acute retinal necrosis syndrome.” Basic Science Lecture Series, Grand Rounds, Jules Stein Eye Institute, Los Angeles, CA

04/96 “Management of suprachoroidal hemorrhage.” Retina Rounds Resident Lecture, Jules Stein Eye Institute,
Los Angeles, CA

05/96 “Ochronosis oculi” Grand Rounds Lecture, Jules Stein Eye Institute, Los Angeles, CA

05/96 “Volume sensitive chloride channels in human retinal pigment epithelium: physiology and clinical significance.” Research and Alumni Day, Jules Stein Eye Institute, Los Angeles, CA

08/97 “Retinal pigment epithelium function in normal and disease states”. Visiting Lecturer, Department of Molucular and Cell Biology, Scripps Clinics and Research Center, San Diego, CA

10/97 “Intravitreal drug delivery for posterior segment disease.” Visiting Lecturer, Department of Ophthalmology, Cleveland Clinic Foundation Cleveland, OH

03/14/98 “Retinal transplantation.” Retina Update 1998, Good Samaritan Hospital, Los Angeles, CA

03/14/98 “Intravitreal drug delivery for posterior segment disease.” Retina Update 1998, Good Samaritan Hospital, Los Angeles, CA

05/12/98 “Water and Ion Transport by he Retinal Pigment Epithelium,” Symposium: “IPE Transplantation: Theoretical and Practical Considerations,” Fort Lauderdale, FL

09/98 “Diagnosis and Management of Ocular Emergencies.” California Medical Center, Los Angeles, CA

10/01/98 “Common Eye Emergencies” Grand Rounds Lecture, Santa Marta Hospital, Los Angeles, CA

11/08/98 “Ophthalmic Manifestation of Systemic Disease in the Pediatric Patient.” Pediatric Grand Rounds, White Memorial Medical Center, Los Angeles, CA.

11/12/98 “AIDS Related Retinopathies.” Grand Rounds Lecture, Good Samaritan Hospital, Los Angeles, CA

11/19/98 “Ocular Emergencies.” Grand Rounds Lecture, White Memorial Medical Center, Los Angeles, CA

12/02/98 “The eye in systemic disease.” Grand Rounds Lecture, Cedars Sinai Medical Center, Beverly Hills, CA

01/04/99 “Diabetic Retinopathy.” Endocrine Grand Rounds, Cedars Sinai Medical Center, Beverly Hills, CA

03/12/99 “Diagnosis and Management of Ocular Trauma.” Grand Rounds Lecture, Northridge Hospital Medical Center, Northridge, CA

03/18/99 “Overview of current research studies on macular degeneration.” Braille Institute Lecture, Pacific Inn, Torrance, CA

03/20/99 “Future of Vitreoretinal management.” Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA

03/20/99 “Panoramic viewing for Vitreoretinal surgery.” Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA

03/20/99 “Subretinal surgery.” Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA

03/10/00 “OCT in Macular Disease,” Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA

03/10/00 “Sub-Macular Surgery,” Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA

03/10/00 “Surgical Management of Proliferative Diabetic Retinopathy,” Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA

03/10/00 “Future Advances in Vitreo-Retinal Surgery,” Retina Update 2000, Good Samaritan Hospital, Los Angeles, CA

09/26/00 “Treatment Update: Diabetic Retinopathy,” Endocrinology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA

10/22/00 “Silicone Oil and Vitreo-Retinal Surgery,” AAO

11/12/00 “Mac Degeneration & Diabetic Retinopathy,” California Optometric Association, Academy Meeting, Monterey, CA

12/5/00 ‘Treatment Update: Macular Degeneration’, Braille Institute, Los Angeles, CA

05/17/01 “Overview of current research studies on retinal diseases”. Braille Institute, Los Angeles, CA

05/17/01 “Update on Macular Diseases,” South Bay Optometric Society Meeting, Torrance, CA

05/18/01 “Update on Diabetic Retinopathy and Advances in Macular Degeneration Therapy,” Rio Hondo Optometric Society Annual In vocational meeting, Cerritos, CA

06/25/01 “Macular Degeneration,” Braille Institute, Los Angeles, CA

08/17/01 “Common Eye Emergencies,” “Ocular Manifestations of Systemic Disease,” “Treatment update: Macular
Degeneration and Diabetic Retinopathy,” Invited Lecturer, Rio Hondo Optometric Society, Las Vegas, NV

03/16/02 “Surgical Management of AMD” Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA

03/16/02 “OCT for Diagnosis for Retinal Disease” Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA

03/16/02 “OCT Management of Complex Vitreoretinal Diseases” Retina Update 2002, Good Samaritan Hospital, Los Angeles, CA

03/16/02 “The Future of V-R Management” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

05/08/02 “Seminar on Macular Degeneration and low vision rehabilitation” Braille Institute, Los Angeles, CA.

03/22/03 “Surgical Management of Macular Degeneration” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “Surgical and Laser Shunting Procedures for Venous Occlusive Diseases” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “OCT Management of Complex Vitreoretinal Diseases” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “Surgical Management of Diabetic Retinopathy” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “The Future of Vitreoretinal Management” Retina Update 2003, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “Surgical Management of Diabetic Retinopathy” Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA

03/22/03 “Surgical Management of Diabetic Retinopathy” Retina Update 1999, Good Samaritan Hospital, Los Angeles, CA

04/16/03 “Optical coherence tomography for diagnosis and treatment of macular disease,” South Bay Optometric Society Annual In vocational Meeting, Guest Lecturer, Torrance, CA

05/24/03 Retina Review, Ophthalmology Assessment Program Preparatory Course, Cedars Sinai Medical Center, Los Angeles, CA

06/16/03 “Overview of the latest research on macular degeneration” Oasis Center and the Braille Institute, Los Angeles, CA.

08/23/03 “Rheopheresis and other novel treatments for macular diseases,” Rio Hondo Optometric Society Clinical Update, Las Vegas, NV

11/22/03 “Clinical trials for macular degeneration” Macular Degeneration Research Foundation, Skirball Cultural Center, Los Angeles, CA.

02/12/04 “The Latest Research on Macular Degeneration,” Braille Institute, Los Angeles, CA.

03/20/04 “Surgical Management of Macular Degeneration” Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA

03/20/04 “OCT Management of Complex Vitreoretinal Diseases,” Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA

03/20/04 “Surgical Management of Diabetic Retinopathy,” Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA

03/20/04 “Progressive pigmented lesion of the macula,” Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA

03/20/04 “The Future of Vitreoretinal Management: Clinical Trials Update” Retina Update 2004, Good Samaritan Hospital, Los Angeles, CA

05/22/04 Retina Review, Ophthalmology Assessment Program Preparatory Course, Cedars Sinai Medical Center, Los Angeles, CA

06/16/04 Retina Update: “Intravitreal Kenalog: A cure all for macular diseases?”, San Bernardino County Optometric Society Meeting, Ontario, CA

06/26/04 “Intravitreal Kenalog injections for management of macular diseases.” Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV

06/26/04 “Rheopheresis and other novel treatments for macular disease.” Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV

06/26/04 “Differential Diagnosis of Macular Diseases.” Guest Lecturer, Rio Hondo Optometric Society Annual Convention, Las Vegas, NV

07/31/04 “Intravitreal Kenalog Injections: A “cure all” for macular diseases?” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/31/04 “AMD and beyond: Differential diagnosis of macular diseases” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/31/04 “Treatment Update: Macular degeneration” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/31/04 “Treatment Update: Diabetic Retinopathy” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/31/04 “Immunologic disorders and retinal disease” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/31/04 “Optical coherence tomography (OCT) for diagnosis and management of macular diseases” Third Annual Chilean Congress of Ophthalmology, Guest Professor, Santiago, Chile

07/25/10 “Retinal Unknowns”, Knott’s Berry Farm Resort Hotel, Buena Park, California

07/25/10 “Ocular Inflammation vs. Infection: How to Differentiate and Prevent”, Knott’s Berry Farm Resort Hotel, Buena Park, California

07/24/11 “Retinal Update: New Surgical and Treatment Options for Retinal Disease”, Rio Hondo, Yorba Linda, California

10/13/11 “New Treatment Options for Retinal Diseases: What You and Your Patients Need to Know”, Annual
Symposium, Torrance, California

10/13/11 “Different Diagnoses of Neuroretinopathies”, Annual Symposium, Torrance, California

10/13/11 “Improving Outcomes for Your Cataract and Refractive Surgery Patients with Retinal Disease”, Annual Symposium, Torrance, California

07/22/12 “New Treatments and Surgical Options for Retinal Disease: What You and Your Patients Need to Know”, Rio Hondo, Yorba Linda, California

Scientific Reviewer

  • Retina Investigative Ophthalmology and Visual ScienceAmerican Journal of Ophthalmology

  • British Journal of Ophthalmology

  • Review of Ophthalmology

  • Society Memberships And Organizations

  • American Academy of Ophthalmology

  • American Society of Retina Specialists

  • Heed and Knapp Fellowship Society

  • American Academy for the Advancement of Science

  • American Medical Association

  • Association for Research in Vision and Ophthalmology

  • Braille Institute

  • Good Samaritan Hospital Continuing Medical Education Board

  • Discovery Fund, Cedars-Sinai Medical Center, Los Angeles, CA

  • Macular Degeneration Foundation, Board of Scientific Advisors

  • Los Angeles County Medical Association

  • Society for Neuroscience

  • Society of Heeds Fellows

  • Ron Michaels Society (of Retinal Specialists)

  • Eye Care America of the AAO

  • Heed and Knapp Fellowship Society